CLINICAL TRIALS PROFILE FOR CALCIPOTRIENE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for calcipotriene
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT02019355 ↗ | Actinic Keratosis Study | Completed | Washington University School of Medicine | Early Phase 1 | 2013-10-01 | The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition. |
| New Indication | NCT02019355 ↗ | Actinic Keratosis Study | Completed | Washington University School of Medicine | Early Phase 1 | 2013-10-01 | The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for calcipotriene
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00279162 ↗ | Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis | Completed | LEO Pharma | Phase 3 | 2005-12-01 | Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patients will receive an ointment containing both calcipotriene plus betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks. The objective is to study the short-term efficacy of the gel, and the short and long-term safety of the gel and the ointment. |
| NCT00437255 ↗ | Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis | Completed | Galderma Laboratories, L.P. | Phase 4 | 2006-08-01 | Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment. |
| NCT00608777 ↗ | Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva) | Terminated | Genentech, Inc. | Phase 4 | 2008-01-01 | The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption. |
| NCT00608777 ↗ | Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva) | Terminated | Derm Research, PLLC | Phase 4 | 2008-01-01 | The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption. |
| NCT00656019 ↗ | Development of Vitamin D as a Therapy for Breast Cancer - Phase 2 | Completed | United States Department of Defense | Phase 2 | 2008-04-01 | This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers. |
| NCT00656019 ↗ | Development of Vitamin D as a Therapy for Breast Cancer - Phase 2 | Completed | Stanford University | Phase 2 | 2008-04-01 | This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers. |
| NCT00817219 ↗ | Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris | Completed | LEO Pharma | Phase 2 | 2009-07-01 | The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for calcipotriene
Condition Name
Clinical Trial Locations for calcipotriene
Trials by Country
Clinical Trial Progress for calcipotriene
Clinical Trial Phase
Clinical Trial Sponsors for calcipotriene
Sponsor Name
